Impact of the suspension and restart of the Dutch breast cancer screening program on breast cancer incidence and stage during the COVID-19 pandemic

被引：53

作者：

Eijkelboom, Anouk H. ^{[1
]}

de Munck, Linda ^{[1
]}

Lobbes, Marc B. I. ^{[2
,3
,4
]}

van Gils, Carla H. ^{[5
]}

Wesseling, Jelle ^{[6
,7
]}

Westenend, Pieter J. ^{[8
]}

Paez, Cristina Guerrero ^{[9
]}

Pijnappel, Ruud M. ^{[10
]}

Verkooijen, Helena M. ^{[11
]}

Broeders, Mireille J. M. ^{[12
,13
]}

Siesling, Sabine ^{[1
,14
]}

机构：

[1] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, Godebaldkwartier 419, NL-3511 DT Utrecht, Netherlands

[2] Zuyderland Med Ctr Sittard Geleen, Dept Med Imaging, Dr H Hoffplein 1, NL-6162 BG Sittard Geleen, Netherlands

[3] Maastricht Univ, Med Ctr, Dept Radiol & Nucl, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands

[4] Maastricht Univ, GROW Sch Oncol & Dev Biol, Univ Singel 40, NL-6220 ER Maastricht, Netherlands

[5] Univ Med Ctr Utrecht, Dept Epidemiol, Julius Ctr Hlth Sci & Primary Care, Univ Weg 100, NL-3584 CG Utrecht, Netherlands

[6] Netherlands Canc Inst Antoni Leeuwenhoek, Div Diagnost Oncol & Mol Pathol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands

[7] Leiden Univ, Med Ctr, Dept Pathol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands

[8] Lab Pathol, Karel Lotsyweg 145, NL-3318 AL Dordrecht, Netherlands

[9] Dutch Breast Canc Soc BVN, Godebaldkwartier 363, NL-3511 DT Utrecht, Netherlands

[10] Univ Med Ctr Utrecht, Dept Radiol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

[11] Univ Med Ctr Utrecht, Div Imaging & Oncol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands

[12] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Geert Grooteplein Zuid 10, NL-6525 GA Nijmegen, Netherlands

[13] Dutch Expert Ctr Screening, Wijchenseweg 101, NL-6538 SW Nijmegen, Netherlands

[14] Univ Twente, Tech Med Ctr, Drienerlolaan 5, NL-7522 NB Enschede, Netherlands

来源：

PREVENTIVE MEDICINE | 2021年 / 151卷

关键词：

COVID-19; Breast cancer incidence; Breast cancer screening; cT-stage; Clinical tumor stage;

D O I：

10.1016/j.ypmed.2021.106602

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The COVID-19 pandemic forced the Dutch national breast screening program to a halt in week 12, 2020. In week 26, the breast program was resumed at 40% capacity, which increased to 60% in week 34. We examined the impact of the suspension and restart of the screening program on the incidence of screen-detected and nonscreen-detected breast cancer. We selected women aged 50-74, diagnosed during weeks 2-35 of 2018 (n = 7250), 2019 (n = 7302), or 2020 (n = 5306), from the Netherlands Cancer Registry. Weeks 2-35 were divided in seven periods, based on events occurring at the start of the COVID-19 pandemic. Incidence of screen-detected and non-screen-detected tumors was calculated overall and by age group, cT-stage, and cTNM-stage for each period in 2020, and compared to the incidence in the same period of 2018/2019 (averaged). The incidence of screen-detected tumors decreased during weeks 12-13, reached almost zero during weeks 14-25, and increased during weeks 26-35. Incidence of non-screen-detected tumors decreased to a lesser extent during weeks 12-16. The decrease in incidence was seen in all age groups and mainly occurred for cTis, cT1, DCIS, and stage I tumors. Due to the suspension of the breast cancer screening program, and the restart at reduced capacity, the incidence of screen-detected breast tumors decreased by 67% during weeks 9-35 2020, which equates to about 2000

引用

页数：10

共 13 条

[1]

Bierley JD., 2017, UICC TNM Classification of Malignant Tumours. Digestive System Tumours, V8th

[2] Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program? [J].